hepatitis%20a%20-and-%20e
HEPATITIS A & E

Hepatitis A route of transmission is through oral-fecal route while in hepatitis E, aside from the oral-fecal route, it is also transmitted through blood transfusion in endemic areas.

Hepatitis A incubation period is 15-50 days and hepatitis E incubation period is 15-60 days.

Hepatitis A & E viruses cause epidemics.

 

Hepatitis%20a%20-and-%20e Management

Prevention

PREVENTION AND POST-EXPOSURE PROPHYLAXIS OF HEPATITIS A and E
Patient Group for Whom Prevention or Post-exposure Prophylaxis is Recommended Recommended Prevention or Post-exposure Prophylaxis Regimen
Prevention
Hepatitis A
Susceptible persons traveling to hepatitis A virus (HAV)-endemic areas
Lab researchers potentially exposed to HAV
Unvaccinated and immunocompromised children (suboptimal response)
Men who have sex with men (MSM)
Illegal drug users (both injection and non-injection drug users)
Homeless individuals
Individuals with potential close contact with an international adoptee
Persons with chronic liver disease, including persons with chronic HBV and HCV infection who have evidence of chronic liver disease
Patients with HIV infection
Hepatitis A Vaccine1
Hepatitis E
Individuals susceptible to HEV infection and HEV-related diseases
Hepatitis E recombinant vaccine (approved only in China)
Post-exposure Prophylaxis
Hepatitis A
Unvaccinated or nonimmune persons exposed to HAV through household or sexual contact or by sharing illegal drugs with a person who has hepatitis A2
Administer Hepatitis A vaccine as soon as possible, within 2 weeks after exposure
A single IM dose of human immunoglobulin (Ig) may be given together with Hepatitis A vaccine to individuals >40 years old, immunocompromised patients, or those with chronic liver disease
1Postvaccination serologic testing is not indicated because most persons respond to the vaccine
2A person who has had 1 dose of hepatitis A vaccine at least 1 month before exposure to HAV does not need Ig
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 4 days ago
Reductions in liver fat and adipose tissue volumes were sustained in patients with type 2 diabetes (T2D) with the addition of the SGLT-2* inhibitor dapagliflozin (DAPA) and the DPP-4** inhibitor saxagliptin (SAXA) to metformin (MET), compared with a regimen comprising glimepiride (GLIM)+MET, according to the extension period results of a phase IIIb trial.